aestheticmedguideAestheticMedGuide
Skin

Post-inflammatory hyperpigmentation after aesthetic procedures

PIH is the most common pigment complication after lasers, peels, microneedling, and injectables in skin of color. What the evidence says about prevention, early treatment, and when to stop devices.

Ran Chen
Ran Chen
12 min read · Published · Evidence-based

You had a laser session to improve your skin. Two to six weeks later, the treated area is darker than before. Not red. Not raw. Dark brown or gray-brown, in patches that follow the pattern of the treatment. This is post-inflammatory hyperpigmentation, or PIH — and it is the most common pigment complication of aesthetic procedures in patients with melanin-rich skin.

PIH is not a burn. It is not scarring. It is the skin's melanocytes responding to inflammation by overproducing melanin. The response is triggered by the controlled injury that lasers, chemical peels, microneedling, and even some injectables deliberately create. In lighter skin tones (Fitzpatrick I–III), the inflammation resolves without visible pigment change. In darker skin tones (Fitzpatrick IV–VI), the same inflammation can activate melanocytes that produce larger and more numerous melanosomes — and the result is visible darkening that can take months to years to resolve.

This article covers why PIH happens after aesthetic procedures, which treatments carry the highest risk, what the evidence says about prevention, and what works — and what does not — for reversing it.

What PIH is and how it develops

Post-inflammatory hyperpigmentation is an acquired excess of melanin in the skin following inflammation or injury. The melanocytes (pigment-producing cells) release excess melanin in response to inflammatory mediators — prostaglandins, leukotrienes, and cytokines — that are produced during tissue injury. This is not a dysfunction. It is a normal inflammatory response that overshoots in patients whose melanocytes are more reactive.

PIH occurs in two layers:

  • Epidermal PIH. Melanin accumulates in the epidermis. Appears light brown to dark brown. More common. Responds better to topical treatment. Wood's lamp examination accentuates the contrast.
  • Dermal PIH. Melanin drops into the dermis through a damaged basement membrane. Appears gray-brown or bluish. Harder to treat. Wood's lamp does not accentuate it.

The depth matters because epidermal melanin turns over with the skin cycle (roughly every 28 days, though PIH takes far longer than one cycle to resolve). Dermal melanin has no efficient clearance mechanism — macrophages engulf melanin particles, but the process is slow, and the pigment can persist for years.

PIH can affect any skin tone. But the frequency, severity, and duration are markedly greater in Fitzpatrick IV–VI. Epidemiological studies show that dyschromias, including PIH, are among the most common reasons patients with skin of color seek dermatologic care.

Which aesthetic procedures trigger PIH

Any procedure that creates inflammation in the skin can trigger PIH. The risk scales with the depth and intensity of the injury, the energy or concentration used, the anatomic site, and the patient's skin type.

Lasers and energy-based devices

Lasers are the most common iatrogenic trigger of PIH. A 2025 systematic review and network meta-analysis published in PMC examined interventions to prevent PIH after laser and energy-based device treatments. The review found that the risk is highest with:

  • Fractional CO2 and Er:YAG resurfacing. Ablative lasers that target water create the deepest tissue injury and carry the highest PIH risk. Studies in Asian populations (predominantly Fitzpatrick III–IV) report PIH incidence of 7–40% depending on density, energy, and post-treatment care. In Fitzpatrick V–VI, the risk is even higher.
  • Q-switched Nd:YAG (532 nm) for pigmentation. The frequency-doubled 532 nm wavelength targets melanin directly and generates heat in the process. In darker skin, the same energy that fragments pigment can stimulate melanocytes to produce more.
  • IPL (intense pulsed light). Broadband light devices are generally contraindicated in Fitzpatrick V–VI due to non-selective heating of melanin. Even in Fitzpatrick IV, IPL can trigger PIH if fluence is too high or pulse duration is too short.
  • Picosecond lasers. The "pico-toning" technique at 1064 nm has a lower PIH profile than Q-switched nanosecond lasers for the same indication, because the ultra-short pulse duration generates less heat. But PIH is still reported, particularly with 532 nm and 755 nm wavelengths in darker skin.

Chemical peels

Chemical peels create controlled chemical injury. PIH risk depends on the acid, concentration, number of layers, and skin type.

  • Superficial peels (glycolic 20–50%, salicylic 20–30%, mandelic, lactic) have a low but real PIH rate. A study of five superficial peels in Fitzpatrick III–VI found a 3.8% complication rate, with Fitzpatrick VI being the most prone.
  • Medium-depth peels (TCA 25–35%, modified Jessner plus TCA) carry significantly higher PIH risk in Fitzpatrick IV–VI. Expert consensus recommends against medium-depth peels in Fitzpatrick IV and above except in experienced hands with aggressive pre-treatment protocols.
  • Deep peels (phenol, Baker-Gordon) are generally contraindicated in darker skin due to the risk of both PIH and permanent hypopigmentation.

Microneedling and RF microneedling

Microneedling creates mechanical micro-injuries. The PIH risk is lower than with lasers because the injury is mechanical rather than thermal. However, radiofrequency microneedling (Morpheus8, Sylfirm X, etc.) adds thermal energy, which increases the PIH risk — especially at deeper needle depths and higher energy settings in Fitzpatrick IV–VI skin.

Injectables

Filler-related PIH is uncommon but can occur, particularly with superficial placement of hyaluronic acid fillers that cause tissue distension or vascular compression. The Tyndall effect (bluish discoloration from superficial HA) is a separate phenomenon but is sometimes confused with PIH by patients.

Prevention: what the evidence actually supports

A 2025 systematic review and network meta-analysis in PMC evaluated interventions to prevent PIH after laser treatments. The key findings:

Sunscreen is the only consistently successful preventative measure across multiple studies. This is not a generic recommendation — it is the finding with the strongest evidence base. Broad-spectrum SPF 30–50 sunscreen, started before treatment and continued daily afterward, is the single intervention that consistently reduces PIH incidence. Physical blockers (zinc oxide, titanium dioxide) are preferred because they also block visible light, which emerging evidence suggests contributes to PIH in darker skin.

Pre-treatment priming with tyrosinase inhibitors. Hydroquinone 4% or azelaic acid 15–20% applied for 2–4 weeks before the procedure may reduce PIH by suppressing melanocyte activity before the inflammatory trigger. The evidence is mixed but supports this approach as a precaution in higher-risk patients.

Topical corticosteroids immediately post-procedure. A randomized controlled trial in Asian patients with Fitzpatrick IV skin found that clobetasol propionate 0.05% applied twice daily for the first 48 hours after CO2 laser resurfacing dramatically reduced PIH incidence compared to standard care. This is a short, aggressive intervention — not a maintenance strategy.

Conservative device settings. Lower fluence, lower density, longer pulse durations, and test spots before full-face treatment all reduce PIH risk. A 2025 review of emerging PIH treatments in dark-skinned individuals emphasized conservative, low-fluence laser techniques combined with robust pre- and post-procedure regimens.

Oral tranexamic acid. TXA has antimelanogenic, anti-inflammatory, and antiangiogenic properties. A 2025 literature review published in PMC found TXA effective and safe across oral, topical, and intradermal formulations for hyperpigmentation disorders including PIH. The evidence for prophylactic use specifically to prevent procedure-related PIH is less robust than for treatment, but clinical practice is moving in this direction.

Topical brimonidine. A vasoconstrictor that reduces post-procedure erythema. The theory is that reducing vascular flow during laser treatment may limit the inflammatory cascade that triggers melanocyte activation. The evidence is preliminary.

Treatment: what works and what does not

Treatment of PIH is stepwise and multimodal. The StatPearls review (NCBI Bookshelf) emphasizes that improvement is slow, treatment lasts months to years, and recurrences are common. Patient education on timeline expectations is essential.

First-line: topical therapy

  • Hydroquinone 4%. The most studied depigmenting agent. FDA-approved for bleaching of hyperpigmented skin. Works by inhibiting tyrosinase, the enzyme that drives melanin synthesis. Should be used in courses of 2–3 months with breaks to reduce the risk of exogenous ochronosis (paradoxical darkening from chronic hydroquinone use). Available by prescription in the US.
  • Azelaic acid 15–20%. A dicarboxylic acid with both anti-melanogenic and anti-inflammatory properties. Safe in pregnancy. A systematic review and meta-analysis found it effective for melasma and PIH with a better safety profile than hydroquinone for long-term use.
  • Topical retinoids (tretinoin, adapalene, tazarotene). Increase cell turnover, disperse melanin, and enhance penetration of other depigmenting agents. Can cause irritation that paradoxically worsens PIH if not introduced gradually.
  • Triple combination cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%). FDA-approved for melasma. The corticosteroid component suppresses the inflammation that hydroquinone and tretinoin can cause. Used off-label for PIH with good evidence.
  • Niacinamide. Blocks melanosome transfer from melanocytes to keratinocytes. Evidence is moderate but safety profile is excellent — can be used long-term without the cycling required for hydroquinone.
  • Cysteamine cream. A non-hydroquinone depigmenting agent with comparable efficacy to 4% hydroquinone in head-to-head trials for melasma. Emerging as a long-term alternative without the ochronosis risk.
  • Tranexamic acid (topical or oral). A 2025 PMC review found TXA effective across all hyperpigmentation disorders including PIH, with a favorable safety profile. Works best in combination with other therapies.

Second-line: procedural interventions

For PIH that does not respond to topical therapy after 3–6 months:

  • Superficial chemical peels. Glycolic acid 30–50%, salicylic acid 20–30%, or mandelic acid peels can accelerate turnover of hyperpigmented epidermis. Must be performed at conservative concentrations to avoid triggering more PIH.
  • Low-fluence 1064 nm Nd:YAG laser ("laser toning"). A large-particle, low-energy approach that fragments melanin without generating significant heat. Safer PIH profile than Q-switched 532 nm or alexandrite in darker skin. Multiple sessions required.
  • 1927 nm thulium laser. A non-ablative fractional laser that targets water in the epidermis with minimal thermal damage. Studies show efficacy for PIH and melasma in darker skin types with lower PIH risk than fractional CO2.
  • Pico-toning at 1064 nm. Picosecond lasers at 1064 nm shatter pigment with minimal heat. Lower PIH risk than nanosecond devices but still requires conservative settings in Fitzpatrick IV–VI.
  • Laser-assisted drug delivery (LADD) with tranexamic acid. A 2025 ODAC presentation by Dr. Pooja Sodha highlighted LADD as a technique that uses fractional laser channels to deliver TXA directly into the dermis, enhancing pigment reduction beyond what topical application alone can achieve. The approach targets both the vascular and melanogenic components of PIH simultaneously.

The vascular component

PIH is not purely a melanin problem. Elevated vascular endothelial growth factor (VEGF) levels in inflamed skin drive both angiogenesis and melanogenesis. This is why targeting blood vessels — with 595-nm pulsed dye laser (PDL) for vascular erythema, or timolol gel to reduce early post-inflammatory erythema — can complement pigment-directed treatments. The vascular approach is particularly relevant in the early phase of PIH, when the underlying erythema is still active. Once the erythema resolves, the pigment component becomes the dominant concern.

What to stop doing

If you have PIH, the first therapeutic intervention is to stop doing the thing that caused it. Continuing to treat PIH with the same device or peel that triggered it is one of the most common mistakes. The inflammatory cycle needs to be broken before pigment can improve.

Other common errors:

  • Over-treating with hydroquinone without breaks. Chronic hydroquinone use can cause exogenous ochronosis — a paradoxical bluish-black hyperpigmentation that is harder to treat than the original PIH.
  • Using irritating actives too aggressively. Retinoids, AHAs, and vitamin C can all cause irritation that worsens PIH. Introduce one at a time, at low concentration, and build up gradually.
  • Skipping sunscreen. UV exposure worsens PIH and prolongs resolution. Visible light may also contribute — tinted sunscreens with iron oxides provide better protection than non-tinted formulations.

The timeline reality

Epidermal PIH typically takes 3–12 months to resolve with treatment. Dermal PIH can take 1–3 years. These timelines frustrate patients who expected the aesthetic procedure to improve their skin, not create a new problem.

The factors that affect resolution time:

  • Depth of melanin deposition. Epidermal resolves faster than dermal.
  • Duration of PIH before treatment started. Early intervention shortens the course.
  • Consistency of photoprotection. Daily SPF 30+ is non-negotiable.
  • Skin type. Fitzpatrick IV–VI skin both develops PIH more easily and resolves it more slowly, because the more active melanocytes take longer to downregulate.
  • Whether the inflammatory trigger persists. Active acne, eczema, or continued device treatments will keep producing new PIH faster than old PIH can resolve.

What to ask your provider

  1. What is my Fitzpatrick skin type, and how does it affect my PIH risk for this specific procedure? If your provider cannot answer this, find a different provider.

  2. What pre-treatment protocol do you use for patients with my skin type? Pre-treatment with a tyrosinase inhibitor and daily sunscreen for 2–4 weeks before the procedure should be standard for Fitzpatrick IV–VI.

  3. What device settings will you use, and why? Conservative settings in higher Fitzpatrick types are not optional. Ask about fluence, density, and whether a test spot will be done.

  4. If I develop PIH, what is the treatment plan? The answer should include topical therapy (hydroquinone or azelaic acid), strict photoprotection, and a realistic timeline — not just "it will fade on its own."

  5. Will you use any intra-procedure or post-procedure interventions to reduce PIH risk? This may include topical corticosteroids for the first 48 hours, brimonidine, or oral tranexamic acid in select cases.

Sources

Topics
MelasmaChemical PeelsLaserPatient SelectionAcne & Scars
Ran Chen
Contributing Editor
Ran Chen

Founder, AestheticMedGuide. Life-sciences operator covering aesthetic devices, injectables, and the industry behind them. Previously global market-access lead across pharma and medtech.

Follow on LinkedIn →

Keep reading from Skin

See all →
Skin · 13 min read

Acne Scar Treatments for Skin of Color: Safety, PIH Risk, and Sequencing

Acne scar treatment in darker skin (Fitzpatrick IV-VI) requires modalities that minimize PIH. RF microneedling and subcision are safest; fractional…

Skin · 10 min read

Chemical Peels for Dark Skin: Safe Acids, Concentrations, and PIH Avoidance

Chemical peels treat hyperpigmentation and acne in Fitzpatrick IV-VI skin when acid type and concentration match melanin-rich skin. Mandelic and…

Devices · 16 min read

Laser Resurfacing for Black Skin: Safe Wavelengths and Settings

Laser resurfacing in Black skin requires matching wavelength and energy to melanin-rich tissue. Non-ablative 1540/1550 nm and 1064 nm Nd:YAG are…